Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.79 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.66 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.66 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.66 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | XBP1 | P17861 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | KIF11 | P52732 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7733701 | 0.89 | L3MBTL1 (1.00) | L3MBTL1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL22059620 | 0.84 | PDK1 (0.72) | L3MBTL1PDK1PDK2PDK3PDK4 | |
| SCHEMBL14466017 | 0.84 | KIF11 (0.66) | L3MBTL1PDK1PDK2PDK3PDK4 | |
| SCHEMBL14256552 | 0.84 | L3MBTL1 (0.73) | L3MBTL1PDK1PDK2PDK3PDK4 | |
| SCHEMBL3736169 | 0.84 | L3MBTL1 (0.73) | L3MBTL1PDK1PDK2PDK3PDK4 | |
| SCHEMBL13756246 | 0.83 | MAPT (0.81) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL2730172 | 0.83 | MAPT (0.81) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL18033762 | 0.81 | L3MBTL1 (0.83) | L3MBTL1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL4110532 | 0.81 | L3MBTL1 (0.83) | L3MBTL1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL1422823 | 0.81 | L3MBTL1 (0.83) | L3MBTL1MAPTALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954705-A | Indole derivative and preparation method thereof | 南阳师范学院 | 2025-05-09 | — | — | CN | claimed |
| CN-119954705-A | Indole derivative and preparation method thereof | 南阳师范学院 | 2025-05-09 | — | — | CN | disclosed |
| CN-113912529-B | Method for synthesizing indole compounds by catalyzing N-aryl amide compounds and vinylene carbonate with ruthenium | 成都大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-113912529-A | Method for synthesizing indole compound by catalyzing N-aryl amide compound and vinylene carbonate with ruthenium | 成都大学 | 2022-01-11 | — | — | CN | disclosed |
| US-10766912-B2 | Silicon-containing compound for resistance to hepatitis C virus infection | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-08 | — | — | US | disclosed |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | ASCENDIS PHARMA A/S (DK) | 2017-08-10 | — | — | US | disclosed |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | ASCENDIS PHARMA A/S (DK) | 2017-08-10 | — | — | US | disclosed |
| US-9624229-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624229-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9416139-B2 | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110213003-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212969-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | L3MBTL1 2124/4885PDK1 1506/4885PDK2 1644/4885 |
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | L3MBTL1 3138/4885PDK1 1939/4885PDK2 1868/4885 |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | DNPEP, PAM, ASNS | L3MBTL1 2318/4885PDK1 1489/4885PDK2 2134/4885 |
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | L3MBTL1 2298/4885PDK1 1139/4885PDK2 1849/4885 |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | L3MBTL1 2632/4885PDK1 1597/4885PDK2 2421/4885 |
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | L3MBTL1 4761/4885PDK1 2835/4885PDK2 2720/4885 |
| US-20110212969-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC10, HDAC1 | L3MBTL1 2662/4885PDK1 2530/4885PDK2 2462/4885 |
| US-20110213003-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC3 | L3MBTL1 2849/4885PDK1 1885/4885PDK2 1705/4885 |
| US-10766912-B2 | Silicon-containing compound for resistance to hepatitis C virus infection | SLC11A2, SLC10A1, SLC39A11 | L3MBTL1 3568/4885PDK1 2525/4885PDK2 3211/4885 |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | L3MBTL1 2633/4885PDK1 526/4885PDK2 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.